379 related articles for article (PubMed ID: 30406152)
1. The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy.
Zhao H; Li Y; Wei D; Luo H
J Immunol Res; 2018; 2018():3673295. PubMed ID: 30406152
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy as an Option for Cancer Treatment.
Rusch T; Bayry J; Werner J; Shevchenko I; Bazhin AV
Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):89-96. PubMed ID: 29026920
[TBL] [Abstract][Full Text] [Related]
3. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of cancers comes of age.
Yousefi H; Yuan J; Keshavarz-Fathi M; Murphy JF; Rezaei N
Expert Rev Clin Immunol; 2017 Oct; 13(10):1001-1015. PubMed ID: 28795649
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
Terranova-Barberio M; Thomas S; Munster PN
Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors side effects and management.
Kourie HR; Klastersky J
Immunotherapy; 2016 Jun; 8(7):799-807. PubMed ID: 27349979
[TBL] [Abstract][Full Text] [Related]
7. Adapting Cancer Immunotherapy Models for the Real World.
Klevorn LE; Teague RM
Trends Immunol; 2016 Jun; 37(6):354-363. PubMed ID: 27105824
[TBL] [Abstract][Full Text] [Related]
8. The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade.
Bersanelli M; Leonetti A; Buti S
Immunotherapy; 2017 Nov; 9(14):1127-1131. PubMed ID: 29067883
[No Abstract] [Full Text] [Related]
9. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.
Overwijk WW
Curr Opin Immunol; 2017 Aug; 47():103-109. PubMed ID: 28806603
[TBL] [Abstract][Full Text] [Related]
10. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Apetoh L; Ladoire S; Coukos G; Ghiringhelli F
Ann Oncol; 2015 Sep; 26(9):1813-1823. PubMed ID: 25922066
[TBL] [Abstract][Full Text] [Related]
11. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy.
Chen Q; Xu L; Liang C; Wang C; Peng R; Liu Z
Nat Commun; 2016 Oct; 7():13193. PubMed ID: 27767031
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune Cardiotoxicity of Cancer Immunotherapy.
Cheng F; Loscalzo J
Trends Immunol; 2017 Feb; 38(2):77-78. PubMed ID: 27919707
[TBL] [Abstract][Full Text] [Related]
13. Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade.
Choi Y; Seok SH; Yoon HY; Ryu JH; Kwon IC
Adv Drug Deliv Rev; 2024 Jun; 209():115306. PubMed ID: 38626859
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges.
Teng F; Kong L; Meng X; Yang J; Yu J
Cancer Lett; 2015 Aug; 365(1):23-9. PubMed ID: 25980820
[TBL] [Abstract][Full Text] [Related]
15. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
Gerber HP; Sapra P; Loganzo F; May C
Biochem Pharmacol; 2016 Feb; 102():1-6. PubMed ID: 26686577
[TBL] [Abstract][Full Text] [Related]
16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of colorectal cancer: new perspectives after a long path.
Correale P; Botta C; Ciliberto D; Pastina P; Ingargiola R; Zappavigna S; Tassone P; Pirtoli L; Caraglia M; Tagliaferri P
Immunotherapy; 2016 Nov; 8(11):1281-1292. PubMed ID: 27993089
[TBL] [Abstract][Full Text] [Related]
18. Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.
Kean LS; Turka LA; Blazar BR
Immunol Rev; 2017 Mar; 276(1):192-212. PubMed ID: 28258702
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.
Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R
Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903
[TBL] [Abstract][Full Text] [Related]
20. Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
Lucca LE; Hafler DA
Immunol Rev; 2017 Mar; 276(1):9-25. PubMed ID: 28258696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
